LONG BEACH, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Oct 16, 2023– Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present new positive data from its Phase 4, open-label trial of VTAMA (tapinarof) cream, 1% for intertriginous plaque psoriasis in adults (N=34)…Read More
Dermavant to Present New Positive Data from Phase 4 Open Label Trial of VTAMA tapinarof Cream 1 for Intertriginous Plaque Psoriasis in Adults and Multiple Clinical Trials of VTAMA cream at the 2023 Fall Clinical Dermatology Conference
